Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs

Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs

Ionis Pharmaceuticals (NASDAQ: IONS) reported second-quarter earnings earlier this week and then followed up on Friday with a disclosure that it's getting full rights back to two of its drugs, inotersen and IONIS-FB-LRx, after GlaxoSmithKline (NYSE: GSK) decided not to license them.

Metric

Q2 2017

Continue reading

Source: Fool.com